Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma

Peking University

Status and phase: Unknown; Phase 2

Conditions: NK/T Cell Lymphoma

Treatments: Drug: Dexamethasone, azacytidine, Pegaspargase, Tislelizumab

Study type: Interventional

Funder types: Other

Identifiers

NCT04899414

DAPT for NKTCL

Details and patient eligibility

About

The optimal first-line treatment for extra-nodal NK/T-cell lymphoma (ENKTL) has not been well-defined. This phase II study aimed to evaluate the efficacy and safety of Dexamethasone, azacytidine, Pegaspargase, Tislelizumab (DAPT) regimen for patients with newly diagnosed advanced stage ENKTL

, non-upper aerodigestive tract NK/T- cell lymphoma（NUAT- NKTCL）and relapsed refractory NK/T cell lymphoma.

Enrollment: 50 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• age 18-70 years ,Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
• patients with confirmed pathological diagnosis of ENKTL as defined by WHO criteria
• at least one measurable lesion
• hemoglobin ≥90 g/l, absolute neutrophil count ≥ 1.5 × 10^9/L, platelets ≥ 75 ×10^9/L), ALT≤ 2 times upper limit of normal, serum creatinine ≤1.5 times upper limit of normal （If the above indicators are abnormal but are caused by the primary disease as assessed by the clinician, the treatment can be enrolled according to the clinical actual situation）
• There was no other serious disease in conflict with this program
• Adequate respiratory function
• Adequate bone marrow function
• Adequate renal and hepatic function
• Not pregnant or nursing ,negative pregnancy test
• No other active malignancy requiring therapy
• No other serious or life-threatening condition deemed unacceptable by the principal investigator
• Life expectancy ≥ 3 months
• Able to understand and sign an informed consent form (ICF).

Exclusion criteria

• NK/T cell lymphoma without confirmed pathological diagnosis;
• Patients with early stage upper aerodigestive tract NK/T- cell lymphoma ;
• Patients with drug allergies or metabolic disorders in the program;
• Any uncontrolled medical diseases (including uncontrolled diabetes, severe heart, lung, liver and kidney dysfunction);
• Severe infection (excluding the following: HBsAg or anti-HBc positive patients taking entecavir, tenofovir and other drugs;HCV RNA positive but taking direct anti-HCV drugs);
• Invasion of primary or secondary central nervous system tumor invasion;
• Contradictions to chemotherapy or radiotherapy;
• Previously other malignancy requiring therapy;
• Peripheral nervous system disorder or mental disorder;
• Incapacity for legal conduct, medical or ethical reasons that affect the continuation of the research;
• Other clinical investigators;
• Combination of anti-tumor drugs outside the research program;
• Participants evaluated inappropriate to participate in this study by principal investigator.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

50 participants in 1 patient group

Stage III/IV or Stage I/II NUAT- NKTCL or Relapsed or Refractory NK/T- cell lymphoma

Experimental group

Description:

4-6 cycles of induction DAPT followed by Auto HSCT as consolidation for CR/PR fit patients ,then by PD-1 as maintenance treatment (up to 16 cycles) for received Auto-HSCT

Treatment:

Drug: Dexamethasone, azacytidine, Pegaspargase, Tislelizumab